Topical administration device

• US 20050054991A1
• Filed: 08/28/2002
• Published: 03/10/2005
• Est. Priority Date: 08/29/2001
• Status: Abandoned Application

• Current Assignee: PharmaKodex Ltd. (Orexo AB)
• Original Assignee: PharmaKodex Ltd. (Orexo AB)
• Inventors: Paterson, Graeme Lindsay Jonathan, Mills, Sharon Ann, Althorpe, Christopher, Staniforth, John Nicholas, Tobyn, Michael John
• Application Number:
  US10/488,169
• Publication Number:
  US 20050054991A1
• Time in Patent Office: Days
• US Class Current: 604/290
• CPC Class Codes: A61M 35/003 Portable hand-held applicators having means for dispensing or spreading integral media hand-held massage devices with liquid delivery A61H7/003
• CPC Class Codes: B65D 83/0011 moved by a screw-shaft

Abstract

Disclosed is a dosing device for topically administering a pharmaceutical formulation to a skin of a mammal, the device comprising a housing capable of holding at least one unit dose of a pharmaceutical formulation comprising a drug and a carrier; an applicator adapted for topically administering a unit dose of the pharmaceutical formulation directly onto the skin; and an actuator, wherein upon actuation, the device is capable of metering a unit dose of the pharmaceutical formulation external to the device, from the housing to the applicator; and methods thereof.

Claims

1. A dosing device for topically administering a pharmaceutical formulation to the skin of a mammal, the device comprising:

a housing capable of storing at least one unit dose of a pharmaceutical formulation comprising a drug incorporated with a pharmaceutically acceptable carrier suitable for topical application onto the skin of said mammal;

an applicator adapted for topically administering a unit dose of the pharmaceutical formulation directly onto the skin; and

an actuator capable of metering a single unit dose of the pharmaceutical formulation from a first position in which the unit dose is stored in the housing to a second position in which the single unit dose is external to the device on the applicator so that the single unit dose can be topically administered.

2. The dosing device of claim 1, wherein said housing is capable of holding multiple unit doses of the pharmaceutical formulation.

3. The dosing device of claim 1, wherein said housing is adapted to hold a semisolid pharmaceutical formulation.

4. The dosing device of claim 3, wherein said housing is adapted to hold a semisolid pharmaceutical formulation selected from the group consisting of an ointment, gel, emulsion, lotion, spray, cream and paste.

5. The dosing device of claim 1, wherein said housing is adapted to hold a liquid pharmaceutical formulation.

6. The dosing device of claim 5, wherein said housing is adapted to hold a liquid pharmaceutical formulation selected from the group consisting of a suspension and a solution.

7. The dosing device of claim 1 wherein upon actuation, the device is capable of metering a unit dose of pharmaceutical formulation from about 0.10 grams to about 5 grams from the housing to the applicator.

8. The dosing device of claim 7 wherein upon actuation, the device is capable of metering a unit dose of pharmaceutical formulation of about 1.0 gram from the housing to the applicator.

9. The dosing device of claim 1 wherein upon a subsequent actuation, an additional unit dose is capable of being delivered from the housing to the applicator, until depletion of the pharmaceutical formulation from the housing.

10. The dosing device of claim 9 further comprising a means for preventing the actuator from functioning after a predetermined number of actuations, for a predetermined time period.

11. The dosing device of claim 10 wherein the desired time period is the dosing interval of the drug.

12. The dosing device of claim 11, wherein the dosing interval is from about 1 hour to about 24 hours.

13. The dosing device of claim 11, wherein the dosing interval is from about 4 hour to about 12 hours.

14. The dosing device of claim 10, wherein the predetermined number of actuation is a number which administers the prescribed amount of pharmaceutical formulation.

15. The dosing device of claim 14, wherein the predetermined number of actuations is one actuation.

16. The dosing device of claim 14, wherein the predetermined number of actuations is more than one actuation.

17. The dosing device of claim 10 wherein the desired time period is at least the time needed to topically administer the previously metered unit dose, in order to prevent accidental actuation during application.

18. The dosing device of claim 1 wherein each unit dose metered from the device does not vary by more than about 10% at room temperature.

19. The dosing device of claim 1 wherein each unit dose metered from the device does not vary by more than about 10% at a temperature from about 20°

C. to about 40°

C.

20. The dosing device of claim 1 wherein each unit dose metered from the device does not vary by more than about 10% at a temperature from about 10°

C. to about 80°

C.

21. The dosing device of claim 1 wherein each unit dose metered from the device does not vary by more than about 10% at a temperature from greater than 0°

C. to less than about 100°

C.

22. The dosing device of claim 1 wherein each unit dose metered from the device does not vary by more than about 5% at room temperature.

23. The dosing device of claim 1 wherein each unit dose metered from the device does not vary by more than about 5% at a temperature from about 20°

C. to about 40°

C.

24. The dosing device of claim 1 wherein each unit dose metered from the device does not vary by more than about 5% at a temperature from about 10°

C. to about 80°

C.

25. The dosing device of claim 1 wherein each unit dose metered from the device does not vary by more than about 5% at a temperature from greater than 0°

C. to less than about 1000 C.

26. The dosing device of claim 1 wherein each unit dose metered from the device does not vary by more than about 1% at room temperature.

27. The dosing device of claim 1 wherein each unit dose metered from the device does not vary by more than about 1% at a temperature from about 20°

C. to about 40°

C.

28. The dosing device of claim 1 wherein each unit dose metered from the device does not vary by more than about 1% at a temperature from about 10°

C. to about 800 C.

29. The dosing device of claim 1 wherein each unit dose metered from the device does not vary by more than about 1% at a temperature from greater than 0°

C. to less than 1000 C.

30. The dosing device of claim 1 wherein said applicator comprises a flat surface.

31. The dosing device of claim 30 wherein said flat surface is angled from a baseline perpendicular to said device when said device is held upright.

32. The dosing device of claim 1 wherein said applicator comprises a convex surface.

33. The dosing device of claim 1 wherein said applicator is comprised of a material which inhibits microbial proliferation.

34. The dosing device of claim 1 wherein said housing is comprised of a material which inhibits microbial proliferation.

35. The dosing device of claim 33 wherein said material comprises a silver containing plastic.

36. The dosing device of claim 1 wherein said applicator is comprised of a non-wetting material which promotes the formation of droplets when exposed to moisture.

37. The dosing device of claim 1 wherein said housing is comprised of a non-wetting material which promotes the formation of droplets when exposed to moisture.

38. The dosing device of claim 36 wherein said material comprises silicone.

39. The device of claim 30 wherein said applicator surface is smooth.

40. The device of claim 30 wherein said applicator surface is ridged.

41. The dosing device of claim 1 further comprising a counter which indicates the number of unit doses remaining in the system.

42. The dosing device of claim 1 further comprising a counter which indicates the number of doses actuated.

43. The device of claim 1 wherein after depletion or partial depletion of said at least one unit dose, said device is capable of being reloaded with at least one additional unit dose.

44. The device of claim 1 wherein after depletion of said at least one unit dose, said device is incapable of being reloaded and is disposable.

45. The device of claim 2 wherein said housing is adapted to contain at least 5 unit doses of said pharmaceutical formulation.

46. The device of claim 2 wherein said housing is adapted to contain from about 5 doses to about 400 unit doses of said pharmaceutical formulation.

47. The device of claim 2 wherein said housing is adapted to contain from about 40 doses to about 120 unit doses of said pharmaceutical formulation.

48. The device of claim 2 wherein said housing is adapted to contain from about 30 doses to about 100 unit doses of said pharmaceutical formulation.

49. The device of claim 2 wherein said housing is adapted to contain about 365 unit doses of said pharmaceutical formulation.

50. The device of claim 2 wherein said housing is adapted to contain about 30 unit doses of said pharmaceutical formulation.

51. The dosing device of claim 1 wherein the applicator includes a valve disposed in an opening of the housing wherein upon actuation, the valve is moveable between an open position to allow discharge of the unit dose through the opening to the applicator and a closed position to seal the opening.

52. The dosing device as recited in claim 51 wherein actuation of the actuator causes a positive pressure in the housing, the positive pressure causing the valve to move from the closed position to the open position.

53. The dosing device of claim 1 wherein said actuator comprises a button wherein actuation of the button causes a unit dose to be discharged from the housing to the applicator.

54. The dosing device as recited in claim 1 wherein the actuator comprises a button, a rack, a pinion, and a lead screw in operative connection with each other, and wherein actuation of the button causes the unit dose to be discharged from the housing to the applicator.

55. The dosing device as recited in claim 51 further comprising a protective cover adapted to cover the valve and applicator in a closed position.

56. The dosing device as recited in claim 51 wherein said valve is movable from the open position to the closed position by a spring mechanism.

57. The dosing device as recited in claim 53 wherein the button is moveable between a non-actuated position and an actuated position.

58. The dosing device as recited in claim 57 further comprising a button spring mechanism which causes the button to return to the non-actuated position after actuation.

59. The dosing device as recited in claim 1 further comprising a non-return mechanism adapted to prevent the actuator from delivering a partial dose and/or contaminating the device.

60. The dosing device as recited in claim 54 wherein the lead screw includes a ratchet logic adapted to reduce a back pressure in the container.

61. The dosing device as recited in claim 54 wherein the lead screw further comprises a valve logic for moving the valve from the closed position to the open position.

62. The dosing device as recited in claim 1 wherein air is substantially prevented from entering the housing during or after actuation.

63. The dosing device as recited in claim 10 wherein said means is a mechanical means or an electrical means.

64. The dosing device as recited in claim 1 wherein the applicator includes a roller ball adapted to roll the unit dose onto the skin.

65. The dosing device as recited in claim 1 wherein the applicator comprises a static surface rigidly connected with the housing and adapted to spread the dose onto the skin.

66. A dosing system comprising a pharmaceutical formulation comprising a drug and a carrier suitable for topical application contained in a device of claims 1-65.

67. The system of claim 66, wherein said pharmaceutical formulation is a semisolid

68. The system of claim 67, wherein said semisolid is selected from the group consisting of an ointment, gel, emulsion, lotion, spray, cream and paste.

69. The system of claim 66, wherein said pharmaceutical formulation is a liquid.

70. The system of claim 69 wherein said liquid is a suspension or a solution.

71. The system of claim 69 wherein said liquid is converted to a foam upon actuation and metering of a unit dose from said housing to said applicator.

72. The system of claim 66, wherein at least about 95% of said drug is absorbed by the skin over a period of less than about 30 minutes after administration.

73. The system of claim 72, wherein at least about 95% of said drug is absorbed by the skin over a period of less than about 20 minutes after administration.

74. The system of claim 72, wherein at least about 95% of said drug is absorbed by the skin over a period of less than about 5 minutes after administration.

75. The system of claim 66, wherein not more than about 50% of said drug is absorbed by the skin over a period of about 12 hours or more after administration.

76. The system of claim 75, wherein not more than about 50% of said drug is absorbed by the skin over a period of about 6 hours or more after administration.

77. The system of claim 75, wherein not more than about 50% of said drug is absorbed by the skin over a period of about 2 hours or more after administration.

78. The system of claim 66 wherein said drug is selected from the group consisting of ACE inhibitors, adenohypophoseal hormones, adrenergic neuron blocking agents, adrenocortical steroids, inhibitors of the biosynthesis of adrenocortical steroids, alpha-adrenergic agonists, alpha-adrenergic antagonists, selective alpha₂-adrenergic agonists, analgesics, antipyretics, anti-inflammatory agents, androgens, local anesthetics, general anesthetics, antiaddictive agents, antiandrogens, antiarrhythmic agents, antiasthmatic agents, anticholinergic agents, anticholinesterase agents, anticoagulants, antidiabetic agents, antidiarrheal agents, antidiuretic agents, antiemetic agents, prokinetic agents, antiepileptic agents, antiestrogens, antifungal agents, antihypertensive agents, antimicrobial agents, antimigraine agents, antimuscarinic agents, antineoplastic agents, antiparasitic agents, antiparkinson agents, antiplatelet agents, antiprogestins, antithyroid agents, antitussives, antiviral agents, antidepressants, azaspirodecanediones, barbituates, benzodiazepines, benzothiadiazides, beta-adrenergic agonists, beta-adrenergic antagonists, selective beta₁-adrenergic antagonists, selective beta₂-adrenergic agonists, bile salts, agents affecting volume and composition of body fluids, butyrophenones, agents affecting calcification, calcium channel blockers, cardiovascular drugs, catecholamines, sympathomimetic drugs, cholinergic agonists, cholinesterase reactivators, dermatological agents, diphenylbutylpiperidines, diuretics, ergot alkaloids, estrogens, ganglionic blocking agents, ganglionic stimulating agents, hydantoins, agents for control of gastric acidity, agents for treatment of peptic ulcers, hematopoietic agents, anti-histamines, 5-hydroxytryptamine antagonists, drugs for the treatment of hyperlipoproteinemia, hypnotics, sedatives, immunosupressive agents, laxatives, bronchodilators, monoamine oxidase inhibitors, neuromuscular blocking agents, organic nitrates, pancreatic enzymes, phenothiazines, progestins, prostaglandins, anti-psychotic agents, retinoids, sodium channel blockers, agents for spasticity, agents for acute muscle spasms, succinimides, xanthines, thrombolytic agents, thyroid agents, tricyclic antidepressants, inhibitors of tubular transport of organic compounds, drugs affecting uterine motility, vasodilators and vitamins.

79. The system of claim 66 wherein said drug is selected from the group consisting of bepridil, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nimodipine, nitredipine, verapamil, dobutamine, isoproterenol, carterolol, labetalol, levobunolol, nadolol, penbutolol, pindolol, propranolol, sotalol, timolol, acebutolol, atenolol, betaxolol, esmolol, metoprolol, albuterol, bitolterol, isoetharine, metaproterenol, pirbuterol, ritodrine, terbutaline, alclometasone, aldosterone, amcinonide, beclomethasone, dipropionate, betamethasone, clobetasol, clocortolone, cortisol, cortisone, corticosterone, desonide, desoximetasone, 11-desoxycorticosterone, 11-desoxycortisol, dexamethasone, diflorasone, fludrocortisone, flunisolide, fluocinolone, fluocinonide, fluorometholone, flurandrenolide, halcinonide, hydrocortisone, medrysone, 6.alpha.-methylprednisolone, mometasone, paramethasone, prednisolone, prednisone, tetrahydrocortisol, triamcinolone, benoxinate, benzocaine, bupivacaine, chloroprocaine, cocaine, dibucaine, dyclonine, etidocaine, lidocaine, mepivacaine, pramoxine, prilocalne, procaine, proparacaine, tetracaine, alfentanil, choroform, clonidine, cyclopropane, desflurane, diethyl ether, droperidol, enflurane, etomidate, halothane, isoflurane, ketamine hydrochloride, meperidine, methohexital, methoxyflurane, morphine, propofol, sevoflurane, thiamylal, thiopental, acetaminophen, allopurinol, apazone, aspirin, auranofin, aurothioglucose, colchicine, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, gold sodium thiomalate, ibuprofen, indomethacin, ketoprofen, meclofenamate, mefenamic acid, meselamine, methyl salicylate, nabumetone, naproxen, oxyphenbutazone, phenacetin, phenylbutazone, piroxicam, salicylamide, salicylate, salicylic acid, salsalate, sulfasalazine, sulindac, tolmetin, acetophenazine, chlorpromazine, fluphenazine, mesoridazine, perphenazine, thioridazine, trifluorperazine, triflupromazine, disopyramide, encainide, flecainide, indecainide, mexiletine, moricizine, phenyloin, procainamide, propafenone, quinidine, tocainide, cisapride, domperidone, dronabinol, haloperidol, metoclopramide, nabilone, prochlorperazine, promethazine, thiethylperazine, trimethobenzamide, buprenorphine, butorphanol, dezocine, diphenoxylate, drocode, hydrocodone, hydromorphone, levallorphan, levorphanol, loperamide, meptazinol, methadone, nalbuphine, nalmefene, nalorphine, naloxone, naltrexone, oxybutynin, pentazocine, isosorbide dinitrate, nitroglycerin, theophylline, phenylephrine, ephidrine, pilocarpine, furosemide, tetracycline, chlorpheniramine, ketorolac, bromocriptine, guanabenz, prazosin, doxazosin, flufenamic acid and pharmaceutically acceptable salts thereof.

80. The system of claim 66 wherein said drug is selected from the group consisting of benzodiazepines, such as alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, demoxepam, diazepam, flumazenil, flurazepam, halazepam, lorazepam, midazolam, nitrazepam, nordazepam, oxazepam, prazepam, quazepam, temazepam, triazolam, and the like;

an antimuscarinic agent such as anisotropine, atropine, clidinium, cyclopentolate, dicyclomine, flavoxate, glycopyrrolate, hexocyclium, homatropine, ipratropium, isopropamide, mepenzolate, methantheline, oxyphencyclimine, pirenzepine, propantheline, scopolamine, telenzepine, tridihexethyl, tropicamide, and the like;

an estrogen such as chlorotrianisene, siethylstilbestrol, methyl estradiol, estrone, estrone sodium sulfate, estropipate, mestranol, quinestrol, sodium equilin sulfate, 17.beta.-estradiol (or estradiol), semi-synthetic estrogen derivatives such as the esters of natural estrogen, such as estradiol-17.beta.-enanthate, estradiol-17.beta.-valerate, estradiol-3-benzoate, estradiol-17.beta.-undecenoate, estradiol 16,17-hemisuccinate or estradiol-17.beta.-cypionate, and the 17-alkylated estrogens, such as ethinyl estradiol, ethinyl estradiol-3-isopropylsulphonate, and the like;

an androgen such as danazol, fluoxymesterone, methandrostenolone, methyltestosterone, nandrolone decanoate, nandrolone phenpropionate, oxandrolone, oxymetholone, stanozolol, testolactone, testosterone, testosterone cypionate, testosterone enanthate, testosterone propionate, and the like;

or a progestin such as ethynodiol diacetate, gestodene, hydroxyprogesterone caproate, levonorgestrel, medroxyprogesterone acetate, megestrol acetate, norethindrone, norethindrone acetate, norethynodrel, norgestrel, progesterone, and pharmaceutically acceptable salts thereof.

81. The system of claim 66, wherein said drug is a locally active agent.

82. The system of claim 81, wherein the locally active agent is for use in the treatment of disorders of the skin selected from the group consisting of psoriasis, eczema, acne, nappy rash, other inflammatory disorders, bacterial infections, viral infections, fungal infections, anaphylactic conditions, malignancies and warts.

83. The system of claim 81, wherein the at least one therapeutic agent is selected from the group consisting of anesthetics, corticosteroids, antibacterial agents, antifungal agents or any therapeutically effective combination thereof.

84. The system of claim 81, wherein the at least one therapeutic agent is selected from the group consisting of tetracaine, benzocaine, lindocaine, hydrocortisone, beclomethasone diproprionate, clobetasol proprionate, fluticasone proprionate, ichthammol, lithium succinate, coal tar, dithranol, benzoyl peroxide, tretinoin, sulphur, vitamin D and derivatives thereof, framycetin, chlortetracycline hydrochloride, fusidic acid, clotrimazole, econazole, amorolfine and terbenafine, or any therapeutically effective combination thereof.

85. The system of claim 83, wherein said anesthetic is selected from the group consisting of bupivacaine, levo-bupivacaine, ropivacaine, benzocaine, dibucaine, procaine, chloroprocaine, prilocalne, mepivacaine, etidocaine, tetracaine, lidocaine, and xylocalne, as well as anesthetically active derivatives, analogs, isomers and mixtures thereof.

86. The system of claim 81, wherein the locally active agent is selected from the group consisting of antiviral agents (e.g., acyclovir and idoxuridine, etc.), antifungal agents (e.g., amphotericin B, clotrimazole, nystatin, ketoconazole, miconazole, butocouazole, haloprogin, etc.), antibiotic agents (penicillins, cephalosporins erythromycin, tetracycline, clindamycin, aminoglycosides, chloramphenicol, polymixin b, bacitracin, neomycin, gentamycin etc.), antiseptics (e.g., povidone-iodine, methylbenzethonium chloride, etc.), antiparasitics (e.g., lindane, anthralin, etc.) analgesic agents (e.g., methylsalicylate, salicylic acid, dyclonine, aloe vera etc.), local anesthetics (e.g., benzocaine, lidocaine, xylocalne, butamben picrate, etc.), anti-inflammatory agents (e.g., steroidal compounds such as dexamethasone, betamethasone, prednisone, prednisolone, triamcinolone, hydrocortisone, alclometasone, amcinonide, diflorasone, etc. as well as non-steroidal anti-inflammatories), anti-itch and irritation-reducing compounds (e.g., antihistamines such as diphenhydramine and psoriasis treatments) burn relief compounds (e.g., o-amino-p-toluenesulfonamide, monoacetate, etc.);

depigmenting agents (e.g., monobenzone); and

hormonal agents (e.g., oestriol).

87. The system of claim 66, wherein said therapeutic agent has non-local activity.

88. The system of claim 87, wherein said therapeutic agent is selected from the group consisting of vasodilators, active substances for the treatment of motion sickness, contraceptive agents, hormone replacement agents, painkillers, and smoking cessation aids, or any therapeutically effective combination thereof.

89. The system of claim 87, wherein said therapeutic agent is selected from the group consisting of nitroglycerin, scopolamine, estradiol, norethisterone, fentanyl and nicotine, or any therapeutically effective combination thereof.

90. The system of claim 66 wherein said carrier comprises a polymer.

91. The system of claim 90 wherein said polymer is selected from the group consisting of sodium alginate, gelatin, corn starch, gum tragacanth, methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, xanthan gum, dextrin, carboxymethylstarch, polyvinyl alcohol, sodium polyacrylate, methoxyethylene-maleic anhydride copolymer, polyvinyl ether, polyvinylpyrrolidone,

92. The system of claim 66 wherein said carrier comprises a wax a fat, an oil or a combination thereof.

93. The system of claim 92 wherein said fat or oil is selected from the group consisting of beeswax, olive oil, cacao butter, sesame oil, soybean oil, camellia oil, peanut oil, beef fat, lard and lanolin.

94. The system of claim 66 wherein said carrier comprises white petrolatum.

95. The system of claim 66 wherein said carrier comprises a paraffin.

96. The system of claim 66 wherein said carrier comprises a higher fatty acid.

97. The system of claim 96 wherein said higher fatty acid is stearic acid.

98. The system of claim 66 wherein said carrier comprises a higher alcohol.

99. The system of claim 98 wherein said higher alcohol is selected from the group consisting of cetyl alcohol, stearyl alcohol and combinations thereof.

100. The system of claim 66 wherein said carrier comprises a polyethylene glycol.

101. The system of claim 66 wherein said carrier comprises water.

108. The device of claim 1 wherein the device is a unitary device.

109. The device of claim 1 wherein the actuator is flush with the surface of the device.

110. The device of claim 1 wherein the actuator is recessed from the surface of the device.

111. The device of claim 1 which can be submersed in water for at least 30 seconds without having the housing infiltrated with water.

112. The device of claim 1 wherein the housing is airtight.

113. The device of claim 1 wherein said housing is comprised of aluminum at the point of contact with the composition.

114. The device of claim 1 wherein said housing is comprised of plastic coated with aluminum at the point of contact with the composition.

115. The device of claim 41 wherein said counter is mechanical

116. The device of claim 41 wherein said counter is electronic.

117. The device of claim 1 comprising a visual aid to determine the number of unit doses remaining in the device.

118. The device of claim 117 wherein said visual aid is a transparent window to the inside of the housing.

119. The device of claim 1 which allows less than about 10% overage of the pharmaceutical composition.

120. The device of claim 1 which allows less than about 5% overage of the pharmaceutical composition.

121. The device of claim 1 which does not require overage of the pharmaceutical composition.

124. The system of claim 66 wherein said drug comprises nitrogen oxide.

102. A method for topically administering a pharmaceutical formulation to the skin of a mammal, the method comprising,

(i) actuating a dosing device for topically administering a pharmaceutical formulation to the skin of a mammal, the device comprising:

a housing storing at least one unit dose of a pharmaceutical formulation comprising a drug incorporated with a pharmaceutically acceptable carrier suitable for topical application onto the skin of said mammal;

an applicator adapted for topically administering a unit dose of the pharmaceutical formulation directly onto the skin; and

an actuator capable of metering a single unit dose of the pharmaceutical formulation from a first position in which the unit dose is stored in the housing to a second position in which the single unit dose is external to the device on the applicator so that the single unit dose can be topically administered; and

(ii) applying the unit dose directly onto the skin of a mammal with the applicator.

103. The method for topically administering a pharmaceutical formulation of claim 102, further comprising actuating said device a second time and administering additional unit doses of said pharmaceutical formulation.

104. The method of claim 102 wherein said drug provides a local effect on the surface of the skin.

105. The method of claim 102 wherein said drug is absorbed and provides a local effect in the region of application.

106. The method of claim 102 wherein said drug is absorbed and provides a systemic effect.

122. The method of claim 102 wherein said applying is self administration.

123. The method of claim 102 wherein said applying is by a caregiver to a patient.

107. A method of preparing a dosing system for topical delivery of a pharmaceutical formulation comprising:

(i) preparing at least one unit dose of a pharmaceutical preparation comprising a drug incorporated with a pharmaceutically acceptable carrier suitable for topical application onto the skin of said mammal; and

(ii) placing the at least one unit dose into a dosing device comprising a housing capable of storing at least one unit dose of a pharmaceutical formulation comprising a drug incoporated with a pharmaceutically acceptable carrier suitable for topical application onto the skin of said mammal;

an applicator adapted for topically administering a unit dose of the pharmaceutical formulation directly onto the skin; and

an actuator capable of metering a single unit dose of the pharmaceutical formulation from a first position in which the unit dose is stored in the housing to a second position in which the single unit dose is external to the device on the applicator so that the single unit dose can be topically administered